isaralgagene civaparvovec vs Migalastat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Fabry Disease

Shared mechanism: Alpha-galactosidase A (GLA / α-Gal A) · full Fabry Disease pipeline

isaralgagene civaparvovec

Developed by PTC Therapeutics and partners

Phase 1/2 in Fabry Diseasegene therapy
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Migalastat · Galafold

Marketed by Amicus Therapeutics and partners

Approved in Fabry Diseasesmall molecule
Partial signal

NCT00925301 · Phase 3 · completed

Participants were randomized and double-blinded to migalastat or placebo, with 34 and 33 participants assigned respectively. The primary endpoint was a kidney biopsy measure of GL-3 inclusions, a surrogate pathology measure rather than a direct clinical outcome; 13 of 32 migalastat-treated participants versus 9 of 32 placebo-treated participants achieved the target reduction, but the comparison was not statistically significant (p=0.2996).

Next expected readout: December 2026 · NCT04020055 (registry estimate)

Reported efficacy

Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants (missed)

Result source: NCT00925301

Results for Fabry Disease

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

isaralgagene civaparvovec: registry results are on file for Fabry Disease, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Migalastat
Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants NCT00925301 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: isaralgagene civaparvovec's landscape · Migalastat's landscape